Rep. Julia Letlow Sells Off Shares of AbbVie Inc. (NYSE:ABBV)

Representative Julia Letlow (R-Louisiana) recently sold shares of AbbVie Inc. (NYSE:ABBV). In a filing disclosed on January 13th, the Representative disclosed that they had sold between $1,001 and $15,000 in AbbVie stock on December 8th. The trade occurred in the Representative’s “MERRILL LYNCH INVESTMENT ACCOUNT #025” account.

Representative Julia Letlow also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Salesforce (NYSE:CRM) on 12/16/2025.
• Sold $1,001 – $15,000 in shares of Pinterest (NYSE:PINS) on 12/16/2025.
• Purchased $1,001 – $15,000 in shares of United Rentals (NYSE:URI) on 12/16/2025.
• Sold $1,001 – $15,000 in shares of Mettler-Toledo International (NYSE:MTD) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of Icon Energy (NASDAQ:ICON) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of Devon Energy (NYSE:DVN) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of AstraZeneca (NASDAQ:AZN) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of Waters (NYSE:WAT) on 12/8/2025.
• Sold $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 12/8/2025.
• Sold $1,001 – $15,000 in shares of Warner Bros. Discovery (NASDAQ:WBD) on 12/8/2025.

AbbVie Stock Performance

Shares of ABBV stock opened at $222.21 on Thursday. The stock has a market capitalization of $392.72 billion, a price-to-earnings ratio of 168.34, a PEG ratio of 0.92 and a beta of 0.36. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The company’s 50-day simple moving average is $226.94 and its 200-day simple moving average is $216.08.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. During the same period in the previous year, the company earned $3.00 earnings per share. AbbVie’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.1%. AbbVie’s dividend payout ratio (DPR) is currently 496.97%.

Institutional Trading of AbbVie

Hedge funds have recently added to or reduced their stakes in the business. Marshall & Sullivan Inc. WA acquired a new stake in AbbVie in the second quarter worth about $25,000. Evolution Wealth Management Inc. acquired a new stake in shares of AbbVie in the 2nd quarter worth approximately $26,000. Chelsea Counsel Co. bought a new position in shares of AbbVie in the third quarter valued at approximately $26,000. Spurstone Advisory Services LLC acquired a new position in shares of AbbVie during the second quarter valued at approximately $28,000. Finally, Texas Capital Bancshares Inc TX bought a new stake in AbbVie during the third quarter worth approximately $31,000. Institutional investors own 70.23% of the company’s stock.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie says it will build out its presence in the fast-growing obesity-treatment market, leveraging a weight‑loss drug it licensed from Danish biotech Gubra — opens a new growth avenue beyond core franchises. AbbVie plans to build out its presence in obesity market
• Positive Sentiment: AbbVie reached a three‑year drug‑pricing pact with the U.S. administration that includes a $100 billion U.S. R&D/investment pledge and exemptions from certain tariffs — reduces policy/tariff risk and signals regulatory cooperation. AbbVie inks latest White House drug pricing deal, scoring tariff reprieve as it makes $100B US investment pledge
• Positive Sentiment: AbbVie agreed to a ~$5.6B licensing partnership with RemeGen to access a PD‑1xVEGF bispecific oncology candidate — expands oncology pipeline and potential future revenue streams. AbbVie pens $5.6B pact with RemeGen to join PD-1xVEGF bispecific battle
• Positive Sentiment: AbbVie is acquiring a drug‑delivery system and an Arizona manufacturing facility from West Pharma and is spending on U.S. manufacturing capacity (including a reported $175M plant) — strengthens supply chain and supports on‑shore production. AbbVie to Acquire Drug Delivery System, Arizona Manufacturing Facility from West Pharma
• Neutral Sentiment: Management’s full transcript from the J.P. Morgan Healthcare Conference provides detail on strategy and pipeline positioning — useful for modeling but no single market‑moving surprise in the transcript itself. AbbVie Inc. (ABBV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Several analyst/market pieces highlight bullish sentiment and long‑term value arguments for ABBV; these can support momentum but reflect secondary commentary rather than new company facts. Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy?
• Neutral Sentiment: AbbVie joined industry calls for the FDA to update post‑approval change rules — a regulatory engagement that could benefit manufacturers broadly if successful but is a longer‑term policy push. AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules
• Negative Sentiment: The U.S. drug‑pricing agreement includes commitments to lower some U.S. prices and Medicaid impacts — this could weigh on near‑term revenue/margins for affected products even as tariff/other risks are reduced. ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon

Wall Street Analyst Weigh In

A number of equities analysts have commented on ABBV shares. Evercore ISI lifted their price objective on shares of AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a report on Monday, September 22nd. JPMorgan Chase & Co. boosted their price objective on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. Cantor Fitzgerald set a $250.00 price objective on shares of AbbVie and gave the stock an “overweight” rating in a research note on Thursday, October 9th. Bank of America upped their target price on AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Finally, Erste Group Bank cut AbbVie from a “buy” rating to a “hold” rating in a research report on Tuesday, October 14th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $246.89.

About Representative Letlow

Julia Letlow (Republican Party) is a member of the U.S. House, representing Louisiana’s 5th Congressional District. She assumed office on April 14, 2021. Her current term ends on January 3, 2027.

Letlow (Republican Party) is running for re-election to the U.S. House to represent Louisiana’s 5th Congressional District. She declared candidacy for the primary scheduled on November 3, 2026.

Julia Letlow earned a doctorate. Letlow’s career experience includes working as a senior administrator with the University of Louisiana at Monroe.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.